$VRX (Valeant Pharmaceuticals International, Inc.)

$VRX {{ '2016-08-09T11:42:05+0000' | timeago}} • Announcement

$VRX's revenues in Emerging Markets segment for 2Q16 were flat as compared to the previous year quarter. This was primarily due to a small decline in the existing business and negative foreign currency exchange impact, which were partially offset by incremental product sales revenue from acquisitions completed in 2015.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$VRX {{ '2017-05-09T13:36:52+0000' | timeago}} • Webcast

$VRX commented that on the gastrointestinal franchise there were some challenges early in 1Q17. The company added that it has dealt with these challenges and added a primary care capability which was critical for the company.

$VRX {{ '2017-05-09T13:23:50+0000' | timeago}} • Webcast

$VRX stated that on a YoY basis in 1Q17, it has seen some brand price increase and was price positive both in the Branded RX and Bausch & Lomb International business. On a constant currency basis, Bausch & Lomb International also had volume growth, but the result was a negative FX.

$VRX {{ '2017-05-09T12:39:56+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q1 2017 highlights

$VRX {{ '2017-05-09T12:15:14+0000' | timeago}} • Announcement

As the drugmaker posted 1Q17 results, $VRX raised its FY17 guidance for non-GAAP EBITDA to $3.60-3.75Bil from previously expected $3.55-3.70Bil. The revised outlook reflects the impact of the sale of the CeraVe, AcneFree and AMBI skincare brands, but not the sale of the Dendreon business expected to close mid-year.

$VRX {{ '2017-05-09T12:12:01+0000' | timeago}} • Announcement

$VRX, whose stock longtime backer Bill Ackman unceremoniously dumped in March this year, delivered $954MM in cash flow from operations in 1Q17. Debt fell by $3.6Bil to $1.3Bil in the quarter, with Bausch Lomb/International segment revenues inching less than 1% up to $1.15Bil. U.S. Diversified Products segment revenues slipped 37% to $355MM.

$VRX {{ '2017-05-09T12:06:34+0000' | timeago}} • Announcement

Total revenues of struggling biotech giant $VRX slipped 11% to $2.1Bil in 1Q17, as a one-time tax benefit of $908MM pushed Valeant to profit with a net attributable income of $628MM from last year's loss of $374MM. Earnings in the quarter were $1.79 per diluted share, compared to the year-ago loss of $1.08 per share.

$VRX {{ '2017-02-28T14:47:35+0000' | timeago}} • Webcast

$VRX said that on the Xifaxan litigation, the company does not comment on the ongoing litigations but expects a trial in 2018. $VRX believes it has got strong intellectual property (IP) on the product & its patents run through 2029. Therefore, the company feels good about the number of patents it has relative to the IP associated with the product.

$VRX {{ '2017-02-28T14:00:42+0000' | timeago}} • Webcast

$VRX said it is looking for low single digit growth in GI business in 2017, before moving to high single digit growth in 2018 and beyond. Additionally, the diversified segment, which is projected to decline 7-10% in 2017 vs. 2016, is expected to still face above average declines in 2018.

$VRX {{ '2017-02-28T13:49:38+0000' | timeago}} • Webcast

$VRX generated under $2.1Bil of net cash from operating activities in calendar year 2016 and reduced total debt by about $1.2Bil. The company ended FY16 with $30.1Bil in principle amount of funded debt outstanding and cash on hand of $542MM. $VRX currently has $875MM drawn on its $1.5Bil revolver.

$VRX {{ '2017-02-28T13:40:48+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q4 2016 Highlights

$VRX {{ '2017-02-28T13:29:10+0000' | timeago}} • Webcast

$VRX said that in 2017, it is expecting following challenges to impact its results. In 1Q17, the company's salesforce turnover increased owing to voluntary and involuntary changes. On the product side in general, $VRX expects Nitropress loss of exclusivity to impact 2017 results. From a process perspective, significant devaluation in Egyptian FX.

$VRX {{ '2017-02-28T13:20:37+0000' | timeago}} • Webcast

In 4Q16, $VRX received FDA approval for Saliq (brodalumab) and also refiled latanoprostene bunod (Vyzulta), a new treatment for glaucoma. The comapny also completed two  successful Phase 3 studies of IDP-118 and licensed EGP-437 combo product from Eyegate Pharmaceuticals for a new eye care indication.

$VRX {{ '2017-02-28T12:40:41+0000' | timeago}} • Announcement

$VRX expects 2017 total revenues of $8.9-9.1Bil and adjusted EBITDA in the range of $3.55-3.70Bil.

$VRX {{ '2017-02-28T12:35:08+0000' | timeago}} • Announcement

$VRX reported a wider 4Q16 loss as reduction in product sales from existing business and negative impact of foreign currency exchange dragged revenue lower. Net loss widened to $515MM or $1.47 per share from $385MM or $1.12 per share last year. Revenue fell to $2.4Bil from $2.76Bil. Non-GAAP EPS decreased to $1.26 from $1.55.

$PRGO {{ '2017-02-07T14:15:18+0000' | timeago}} • Announcement

$PRGO filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for the generic version of Onexton gel to treat comedonal (non-inflammatory) and inflammatory acne. $PRGO has notified $VRX North America LLC and Dow Pharmaceutical Sciences, the owner of both the NDA and patents listed in FDA's Orange Book, of its filing.

$VRX {{ '2016-11-08T15:20:04+0000' | timeago}} • Webcast

$VRX took some price increases in October. The overall price increase for the company on an annualized basis was approx. 2%. $VRX plans to do single digit price increases and stay below the five-year weighted average of branded pharma pricing. The company realizes about 60-65% of price increases after rebates and discounts.

$VRX {{ '2016-11-08T15:10:11+0000' | timeago}} • Webcast

$VRX received a warning letter from the FDA regarding inspections held in February and September 2016 at its Rochester facility. The company is working with the FDA to resolve the issue at the earliest. The issue is specific to some medical devices at the site and does not impact the production or sales of the products at the facility.

$VRX {{ '2016-11-08T14:42:38+0000' | timeago}} • Webcast

$VRX expects the Bausch Lomb/International business to be better in 4Q16 compared to 3Q16. In the Branded Rx segment, revenues for the gastrointestinal and dermatology businesses are expected to be down in 4Q16 versus 3Q16. In the Diversified Products segment, a number of products are expected to be down in 4Q16.

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 2:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm
OMER (Omeros Corporation)
Wednesday, May 10 2017 - 8:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, April 27 2017 - 2:00pm

AlphaGraphics you may like